emapalumab (NI-0501)

	Next higher product group	bispecific antibody
	Status	2017-03-27 development p3 existent
	Organisation	Novimmune S.A.

Novimmune S.A.. (3/27/17). "Press Release: Novimmune Opens a Branch Office in Basel". Geneva & Basel.

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, announced today the opening of its branch office in Basel. The Novimmune premises at Dufourstrasse 11 will host the clinical development team and other functions to progress Novimmune’s lead compound Emapalumab towards filing for a marketing authorisation and its subsequent commercial launch in the US and Europe.

“Novimmune is evolving dynamically and Basel, one of the centers for life sciences in Switzerland, is the ideal complement to our Geneva research and early stage development headquarters. While we continue to build our R&D pipeline in Geneva, we are gathering a strong team in Basel to drive the clinical development of our lead medicine for the treatment of young infants and children suffering from a severe and often life-threatening disease“, says Eduard Holdener, Chairman and CEO of Novimmune.

Emapalumab (NI-0501) is currently in phase 2/3 of clinical development to treat primary Hemo-phagocytic Lymphohistiocytosis HLH, a life-threatening disease of severe hyperinflammation which mainly occurs in children. In June 2016, Emapalumab was declared eligible for PRIME (PRIority MEdicine) status by the European Medicines Agency (EMA), just three months after the US Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation to the same compound.

About Novimmune

Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and runs a branch office in Basel. The company currently employs 130 people. More information is available on the company website at www.novimmune.com.

Contact:
Adrian Mills
+41 (0) 61 201 13 27
amills@novimmune.com